卡莫氟联合放射治疗食管癌的初步临床研究

Clinical study of carmofour concurrent with radiotherapy for esophageal cancer

目的:研究食管癌患者放疗同时应用卡莫氟治疗对药物的耐受性和耐受剂量,观察毒副反应与剂量的关系,同时观察放疗联合卡莫氟的初步疗效。方法:36例食管癌患者,3例因卡莫氟副反应停用,可评价患者33例。放疗采用常规放疗或三维适形放疗。卡莫氟从每日100mg3次/日(6例)为第一个剂量组,第二个剂量组为150mg3次/日(7例),第三个剂量组为200mg3次/日(23例),用于放疗全程。结果:主要的毒副反应为食管炎、血液学毒性、皮肤反应,但患者均能耐受。全组CR率15.2%,PR率63.6%,NC率21.2%。有效率78.8%。中位生存时间为15个月,2年生存率为25.4%。结论:在食管癌放疗联合卡莫氟治疗中,卡莫氟三个剂量组毒性反应均在可接受范围,卡莫氟剂量200mg3次/日可以耐受。

Objective：To study the tolerance, tolerated dose, adverse effects and initial efficacy of carmofour concurrent with radiotherapy in patients with esophageal cancer. Methods：Total 36 patients, 3 patients were excluded because of allergy to carmofour, 33 patients completed the treatment. Conformal radiotherapy and conventional radiotherapy were given. Carmofour was given from 100mg Tid to 200mg Tid during the whole radiotherapy. Results：The main adverse effects were esophagitis, hematoxicity and dermoreaction, which patients could tolerate. The CR rate was 15.2%, PR rate was 63.6%, NC rate was 21.2%. The overall response rate was 78.8%. The median survival time was 14 months and 2-year-survival rate was 25.4%. Conclusion：The patients with esophageal cancer can tolerate radiotherapy concurrent with carmofour. In the concurrent chemoradiotherapy, carmofour with 200mg three times evely day was tolerable.